Goldman Sachs
ONCY

Goldman Sachs’s Oncolytics Biotech ONCY Stock Holding History

Goldman Sachs’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-169,899
Closed -$148K – 6851
2025
Q4 		$148K Sell
169,899
-38,799
-19% -$41.9K ﹤0.01% 6116
2025
Q3 		$292K Buy
208,698
+78,500
+60% +$87.9K ﹤0.01% 5763
2025
Q2 		$101K Buy
130,198
+21,100
+19% +$11.2K ﹤0.01% 5816
2025
Q1 		$60K Buy
109,098
+7,700
+8% +$5.63K ﹤0.01% 5866
2024
Q4 		$92.7K Buy
101,398
+16,400
+19% +$17.1K ﹤0.01% 5777
2024
Q3 		$74K Buy
84,998
+1,400
+2% +$1.38K ﹤0.01% 5602
2024
Q2 		$82.8K Hold
83,598
– – ﹤0.01% 5420
2024
Q1 		$88.6K Buy
+83,598
New +$93.4K ﹤0.01% 5263
2021
Q2 		– Sell
-10,300
Closed -$39K – 6416
2021
Q1 		$39K Buy
+10,300
New +$30.7K ﹤0.01% 5967

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs's ONCY Position: Q1 2026 in Review

Goldman Sachs sold out of Oncolytics Biotech (ONCY) in Q1 2026, closing a stake of 169,899 shares — an estimated $148K sold.

Goldman Sachs first reported a position in ONCY in Q1 2021 and held it in 9 quarters. The position peaked at $292K in Q3 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Goldman Sachs reported no remaining Oncolytics Biotech position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 169,899 Oncolytics Biotech shares in Q1 2026, an estimated $148K.
  • Goldman Sachs first reported a position in Oncolytics Biotech in Q1 2021 and held it in 9 quarters.
  • Goldman Sachs's Oncolytics Biotech position peaked at $292K in Q3 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.